Page last updated: 2024-12-08
bts 54 505
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
BTS 54 505: metabolite of sibutramine; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 134771 |
| CHEMBL ID | 1597911 |
| SCHEMBL ID | 2105 |
| MeSH ID | M0232589 |
Synonyms (46)
| Synonym |
|---|
| bts-54505 |
| bts-54 505 |
| didesmethylsibutramine hydrochloride |
| cyclobutanemethanamine, 1-(4-chlorophenyl)-alpha-(2-methylpropyl)-, hydrochloride |
| n-didesmethylsibutramine hydrochloride |
| xjh8pk8xyh , |
| didesmethyl sibutramine hydrochloride |
| unii-xjh8pk8xyh |
| bts 54505 |
| NCGC00092371-01 |
| bts 54 505 |
| 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride |
| 84484-78-6 |
| FT-0641961 |
| AKOS015894234 |
| SCHEMBL2105 |
| CHEMBL1597911 |
| n-di-desmethyl sibutramine hydrochloride |
| bts 54-505 |
| 1-[1-(4-chloro-phenyl)-cyclobutyl]-3-methyl-butylamine hydrochloride |
| 1-(4-chlorophenyl)-?-(2-methylpropyl)cyclobutanemethanamine hydrochloride |
| bts 54-505 hydrochloride |
| 1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutan-1-amine hydrochloride |
| cyclobutanemethanamine, 1-(4-chlorophenyl)-.alpha.-(2-methylpropyl)-, hydrochloride |
| 1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutylamine hydrochloride |
| (1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutan-1-yl)amine hydrochloride |
| didemethylsibutramine hydrochloride |
| bts-54-505 |
| cyclobutanemethanamine, 1-(4-chlorophenyl)-.alpha.-(2-methylpropyl)-, hydrochloride (1:1) |
| 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine;hydrochloride |
| (1rs)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine hydrochloride (n,n-didesmethylsibutramine hydrochloride) |
| (1rs)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine hydrochloride; sibutramine hydrochloride monohydrate imp. g (pharmeuropa) as hydrochloride; n,n-didesmethylsibutramine hydrochloride; didesmethylsibutramine hydrochloride; sibutramine hydrochlor |
| didesmethylsibutramine hydrochloride 1.0 mg/ml in methanol (as free base) |
| 1-(4-chlorophenyl)-a-(2-methylpropyl)cyclobutanemethanamine hydrochloride |
| BCP15592 |
| didesmethyl (alphas)-sibutramine hydrochloride |
| didesmethyl (alphar)-sibutramine hydrochloride |
| AS-6164 |
| n,n-didesmethyl sibutramine hydrochloride |
| Q27293871 |
| sibutramine-n,n-bisdesmethyl hydrochloride 100 microg/ml in acetonitrile |
| 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutan-1-amine--hydrogen chloride (1/1) |
| DTXSID801004760 |
| SB82437 |
| didesmethylsibutramine-d7hydrochloride |
| E98721 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "To evaluate the pharmacokinetic profiles of the pharmacologically active primary amine metabolite of sibutramine, N-di-desmethyl sibutramine (BTS 54505) in Chinese origin." | ( Pharmacokinetics of sibutramine hydrochloride in Chinese healthy volunteers. Chen, HZ; Chen, J; Huang, X; Jiang, XG; Lu, W; Rong, ZX, 2003) | 0.32 |
| "Various pharmacokinetic parameters including AUC0-t, AUC0-infinity, Cmax, Tmax, T1/2, Kelm and MRT were determined for both test and reference capsules and found to be in good agreement with literature values." | ( Pharmacokinetics of sibutramine hydrochloride in Chinese healthy volunteers. Chen, HZ; Chen, J; Huang, X; Jiang, XG; Lu, W; Rong, ZX, 2003) | 0.32 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (23)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 31.6228 | 0.0126 | 10.6917 | 88.5700 | AID887 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 0.3162 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 12.4435 | 31.6228 | AID902 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 10.0000 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 1.5849 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 10.0000 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 10.0000 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 1.5849 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (21)
Molecular Functions (8)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| iron ion binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| calcium ion binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| protein binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| lipid binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| linoleate 13S-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| arachidonate 8(S)-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| arachidonate 15-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| linoleate 9S-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (8)
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.28) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||